Skip to main content
. 2021 Oct 8;11:681905. doi: 10.3389/fonc.2021.681905

Table 3.

Univariate analysis for factors associated with pCR in the training cohort.

Characteristics Non-pCR (n = 472) pCR (n = 74) p-value
Age (y) 0.306
 <50 266 (56.4) 37 (50.0)
 ≥50 206 (43.6) 37 (50.0)
Menopause 0.561
 Yes 181 (38.3) 31 (41.9)
 No 291 (61.7) 43 (58.1)
Chemotherapy cycles 0.947
 3 15 (3.2) 2 (2.7)
 4 422 (89.4) 66 (89.2)
 5-8 35 (7.4) 6 (8.1)
Histological type 0.609
 Ductal 453 (96.0) 70 (94.6)
 Lobular 7 (1.5) 1 (1.4)
 Others 12 (2.5) 3 (4.1)
Tumor size 0.007
 T1 46 (9.7) 16 (21.6)
 T2 325 (68.9) 48 (64.9)
 T3 101 (21.4) 10 (13.5)
Clinical nodal status <0.001
 Negative 181 (38.3) 54 (73.0)
 Positive 291 (61.7) 20 (27.0)
Histological Grade 0.011
 I 26 (5.5) 11 (14.9)
 II 358 (75.8) 49 (66.2)
 III 88 (18.6) 14 (18.9)
ER <0.001
 Negative 164 (34.7) 42 (56.8)
 Positive 308 (65.3) 32 (43.2)
PR <0.001
 Negative 226 (47.9) 54 (73.0)
 Positive 246 (52.1) 20 (27.0)
HER2 status 0.431
 Negative 264 (55.9) 29 (39.2)
 Positive 208 (44.1) 45 (60.8)
Ki67 expression (%) <0.001
 <14 158 (33.5) 9 (12.2)
 ≥14 314 (66.5) 65 (87.8)
Molecular subtypes <0.001
 Luminal 210 (44.5) 20 (27.0)
 Luminal/HER2 109 (23.1) 14 (18.9)
 HER2 99 (21.0) 15 (20.3)
 TNBC 54 (11.4) 25 (33.8)
ALB 0.765
 <40 178 (37.7) 34 (45.9)
 ≥40 294 (62.3) 40 (54.1)
ALP 0.823
 <100 430 (91.1) 68 (91.9)
 ≥100 42 (8.9) 6 (8.1)
AAPR 0.030
 <0.583 210 (44.5) 23 (31.1)
 ≥0.583 262 (55.5) 51 (68.9)

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; ALB, albumin; ALP, alkaline phosphatase; AAPR, albumin-to-alkaline phosphatase ratio; pCR, pathologic complete response.